-
1
-
-
0028775544
-
The treatment of multiple myeloma
-
PID: 8289856, COI: 1:STN:280:DyaK2c7hvFWntA%3D%3D
-
Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489
-
(1994)
N Engl J Med
, vol.330
, pp. 484-489
-
-
Alexanian, R.1
Dimopoulos, M.2
-
2
-
-
0025294041
-
Renal failure in multiple myeloma. Pathogenesis and prognostic implications
-
PID: 2383164, COI: 1:STN:280:DyaK3czktlGqsg%3D%3D
-
Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695
-
(1990)
Arch Intern Med
, vol.150
, pp. 1693-1695
-
-
Alexanian, R.1
Barlogie, B.2
Dixon, D.3
-
3
-
-
84919469114
-
Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules
-
Berdeja JG, Savona MR, Chu L, Essell J, Murphy P, Bauer T, Raefsky E, Boccia RV, Flinn IW (2013) Bendamustine, bortezomib and dexamethasone (BBD) as first-line treatment of patients (pts) with multiple myeloma who are not candidates for high dose chemotherapy: toxicity comparison of two dose schedules. Blood (Abstract) 122:3193
-
(2013)
Blood (Abstract)
, vol.122
, pp. 3193
-
-
Berdeja, J.G.1
Savona, M.R.2
Chu, L.3
Essell, J.4
Murphy, P.5
Bauer, T.6
Raefsky, E.7
Boccia, R.V.8
Flinn, I.W.9
-
4
-
-
84872512168
-
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
-
PID: 23150919, COI: 1:CAS:528:DC%2BC3sXht1Cgsrg%3D
-
Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321–330
-
(2013)
Br J Haematol
, vol.160
, pp. 321-330
-
-
Berenson, J.R.1
Yellin, O.2
Bessudo, A.3
Boccia, R.V.4
Noga, S.J.5
Gravenor, D.S.6
Patel-Donnelly, D.7
Siegel, R.S.8
Kewalramani, T.9
Gorak, E.J.10
Nassir, Y.11
Swift, R.A.12
Mayo, D.13
-
5
-
-
49449107318
-
Pathogenesis and treatment of renal failure in multiple myeloma
-
PID: 18528426, COI: 1:CAS:528:DC%2BD1cXpslSnur4%3D
-
Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485–1493
-
(2008)
Leukemia
, vol.22
, pp. 1485-1493
-
-
Dimopoulos, M.A.1
Kastritis, E.2
Rosinol, L.3
Blade, J.4
Ludwig, H.5
-
6
-
-
77449137146
-
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors
-
PID: 19717380, COI: 1:CAS:528:DC%2BD1MXhtF2qs73N
-
Dimopoulos MA, Roussou M, Gavriatopoulou M (2009a) Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib based regimes: identification of predictive factors. Clin Lymphoma Myeloma 9:302–306
-
(2009)
Clin Lymphoma Myeloma
, vol.9
, pp. 302-306
-
-
Dimopoulos, M.A.1
Roussou, M.2
Gavriatopoulou, M.3
-
7
-
-
74949121208
-
VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study
-
PID: 19858394, COI: 1:CAS:528:DC%2BC3cXht1agsLo%3D
-
Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF (2009b) VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 27:6086–6093
-
(2009)
J Clin Oncol
, vol.27
, pp. 6086-6093
-
-
Dimopoulos, M.A.1
Richardson, P.G.2
Schlag, R.3
Khuageva, N.K.4
Shpilberg, O.5
Kastritis, E.6
Kropff, M.7
Petrucci, M.T.8
Delforge, M.9
Alexeeva, J.10
Schots, R.11
Masszi, T.12
Mateos, M.V.13
Deraedt, W.14
Liu, K.15
Cakana, A.16
van de Velde, H.17
San Miguel, J.F.18
-
8
-
-
79951891171
-
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group
-
PID: 20956629
-
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J-P, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau J-L, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Gavo M, Rajkumar SV, Durie BGM, Miguel JS (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol 28:4976–4984
-
(2010)
J Clin Oncol
, vol.28
, pp. 4976-4984
-
-
Dimopoulos, M.A.1
Terpos, E.2
Chanan-Khan, A.3
Leung, N.4
Ludwig, H.5
Jagannath, S.6
Niesvizky, R.7
Giralt, S.8
Fermand, J.-P.9
Blade, J.10
Comenzo, R.L.11
Sezer, O.12
Palumbo, A.13
Harousseau, J.-L.14
Richardson, P.G.15
Barlogie, B.16
Anderson, K.C.17
Sonneveld, P.18
Tosi, P.19
Gavo, M.20
Rajkumar, S.V.21
Durie, B.G.M.22
Miguel, J.S.23
more..
-
9
-
-
0016804136
-
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
-
PID: 1182674, COI: 1:STN:280:DyaE28%2FktFCqtA%3D%3D
-
Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854
-
(1975)
Cancer
, vol.36
, pp. 842-854
-
-
Durie, B.G.1
Salmon, S.E.2
-
10
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
PID: 16855634, COI: 1:STN:280:DC%2BD28rgt1aqtA%3D%3D
-
Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV, International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473
-
(2006)
Leukemia
, vol.20
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
Bladé, J.4
Barlogie, B.5
Anderson, K.6
Gertz, M.7
Dimopoulos, M.8
Westin, J.9
Sonneveld, P.10
Ludwig, H.11
Gahrton, G.12
Beksac, M.13
Crowley, J.14
Belch, A.15
Boccadaro, M.16
Cavo, M.17
Turesson, I.18
Joshua, D.19
Vesole, D.20
Kyle, R.21
Alexanian, R.22
Tricot, G.23
Attal, M.24
Merlini, G.25
Powles, R.26
Richardson, P.27
Shimizu, K.28
Tosi, P.29
Morgan, G.30
Rajkumar, S.V.31
International Myeloma Working Group32
more..
-
11
-
-
77955452192
-
Velcade, intravenous cyclophosphamide and dexamethasone (VCD) Induction for previously untreated multiple myeloma (German DSMM XIa Trial
-
Einsele H, Liebisch P, Langer C, Kropff M, Wandt H, Jung W, Kröger N, Engelhardt M, Ostermann H, Mügge L-O, Wolf H–H, Hart C, Metzner B, Kaufmann M, Gramatzki M, Hertenstein B, Fischer Th, Weisel K, Dölken G, Brugger W, Gollasch H, Maschmeyer G, Pfreundschuh M, Schmitz N, Sezer O, Heidemann E, Jäger E, Kahl C, Kiani A, Dechow T, Rösler W, Simon JP, Dürk H, Pflüger KH, Bentz M, Hess G, Mergenthaler HG, Straka C, Hempel D, Salwender HJ, Fingerle-Rowson G, Knop S (2009) Velcade, intravenous cyclophosphamide and dexamethasone (VCD) Induction for previously untreated multiple myeloma (German DSMM XIa Trial. Blood (ASH Annual Meeting Abstracts) 114:131
-
(2009)
Blood (ASH Annual Meeting Abstracts)
, vol.114
, pp. 131
-
-
Einsele, H.1
Liebisch, P.2
Langer, C.3
Kropff, M.4
Wandt, H.5
Jung, W.6
Kröger, N.7
Engelhardt, M.8
Ostermann, H.9
Mügge, L.-O.10
Wolf, H.–H.11
Hart, C.12
Metzner, B.13
Kaufmann, M.14
Gramatzki, M.15
Hertenstein, B.16
Fischer, T.17
Weisel, K.18
Dölken, G.19
Brugger, W.20
Gollasch, H.21
Maschmeyer, G.22
Pfreundschuh, M.23
Schmitz, N.24
Sezer, O.25
Heidemann, E.26
Jäger, E.27
Kahl, C.28
Kiani, A.29
Dechow, T.30
Rösler, W.31
Simon, J.P.32
Dürk, H.33
Pflüger, K.H.34
Bentz, M.35
Hess, G.36
Mergenthaler, H.G.37
Straka, C.38
Hempel, D.39
Salwender, H.J.40
Fingerle-Rowson, G.41
Knop, S.42
more..
-
12
-
-
12944315569
-
GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide
-
IARC Press, Lyon:
-
Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer base No 5 Version 2.0. IARC Press, Lyon
-
(2004)
IARC Cancer base No 5 Version 2.0
-
-
Ferlay, J.1
Bray, F.2
Pisani, P.3
Parkin, D.M.4
-
13
-
-
80053020928
-
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group
-
PID: 21844497, COI: 1:CAS:528:DC%2BC3MXhtlWqsLrP
-
Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 29:3559–3566
-
(2011)
J Clin Oncol
, vol.29
, pp. 3559-3566
-
-
Fischer, K.1
Cramer, P.2
Busch, R.3
Stilgenbauer, S.4
Bahlo, J.5
Schweighofer, C.D.6
Böttcher, S.7
Staib, P.8
Kiehl, M.9
Eckart, M.J.10
Kranz, G.11
Goede, V.12
Elter, T.13
Bühler, A.14
Winkler, D.15
Kneba, M.16
Döhner, H.17
Eichhorst, B.F.18
Hallek, M.19
Wendtner, C.M.20
more..
-
14
-
-
0036340122
-
Metabolism and mechanisms of action of bendamustine: rationales for combination therapies
-
PID: 12170425, COI: 1:CAS:528:DC%2BD38Xmsl2is7g%3D
-
Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(Suppl. 13):4–11
-
(2002)
Semin Oncol
, vol.29
, pp. 4-11
-
-
Gandhi, V.1
-
15
-
-
33646986211
-
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO # 19)
-
PID: 16088404, COI: 1:STN:280:DC%2BD2MnkvFemsg%3D%3D
-
Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Muller C, Muller C (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO # 19). J Cancer Res Clin Oncol 132:105–112
-
(2006)
J Cancer Res Clin Oncol
, vol.132
, pp. 105-112
-
-
Herold, M.1
Schulze, A.2
Niederwieser, D.3
Franke, A.4
Fricke, H.J.5
Richter, P.6
Freund, M.7
Ismer, B.8
Dachselt, K.9
Boewer, C.10
Schirmer, V.11
Weniger, J.12
Pasold, R.13
Winkelmann, C.14
Klinkenstein, C.15
Schulze, M.16
Arzberger, H.17
Bremer, K.18
Hahnfeld, S.19
Schwarzer, A.20
Muller, C.21
Muller, C.22
more..
-
16
-
-
34547706021
-
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
-
PID: 17488666, COI: 1:CAS:528:DC%2BD2sXhtFKrsrjN
-
Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA (2007) Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546–549
-
(2007)
Haematologica
, vol.92
, pp. 546-549
-
-
Kastritis, E.1
Anagnostopoulos, A.2
Roussou, M.3
Gika, D.4
Matsouka, C.5
Barmparousi, D.6
Grapsa, I.7
Psimenou, E.8
Bamias, A.9
Dimopoulos, M.A.10
-
17
-
-
70349330220
-
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia
-
PID: 19652068, COI: 1:CAS:528:DC%2BD1MXht1WisbnO
-
Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(26):4378–4384
-
(2009)
J Clin Oncol
, vol.27
, Issue.26
, pp. 4378-4384
-
-
Knauf, W.U.1
Lissichkov, T.2
Aldaoud, A.3
Liberati, A.4
Loscertales, J.5
Herbrecht, R.6
Juliusson, G.7
Postner, G.8
Gercheva, L.9
Goranov, S.10
Becker, M.11
Fricke, H.J.12
Huguet, F.13
Del Giudice, I.14
Klein, P.15
Tremmel, L.16
Merkle, K.17
Montillo, M.18
-
18
-
-
25444512381
-
The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy
-
PID: 16154860, COI: 1:CAS:528:DC%2BD2MXhtFGrtLjN
-
Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H (2005) The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90:1287–1288
-
(2005)
Haematologica
, vol.90
, pp. 1287-1288
-
-
Knop, S.1
Straka, C.2
Haen, M.3
Schwedes, R.4
Hebart, H.5
Einsele, H.6
-
19
-
-
84919481203
-
Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V
-
Krebs in Deutschland 2009/2010. 9. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Berlin (2013), 120–123
-
(2013)
Berlin
, pp. 120-123
-
-
-
20
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
PID: 17975015, COI: 1:CAS:528:DC%2BD1cXivFaktrk%3D
-
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Rusell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516–2520
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
Lacy, M.Q.4
Hayman, S.R.5
Buadi, F.K.6
Zeldenrust, S.R.7
Dingli, D.8
Rusell, S.J.9
Lust, J.A.10
Greipp, P.R.11
Kyle, R.A.12
Gertz, M.A.13
-
21
-
-
0037216353
-
Review of 1027 patients with newly diagnosed multiple myeloma
-
PID: 12528874
-
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 21-33
-
-
Kyle, R.A.1
Gertz, M.A.2
Witzig, T.E.3
Lust, J.A.4
Lacy, M.Q.5
Dispenzieri, A.6
Fonseca, R.7
Rajkumar, S.V.8
Offord, J.R.9
Larson, D.R.10
Plevak, M.E.11
Therneau, T.M.12
Greipp, P.R.13
-
22
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group
-
PID: 10075613, COI: 1:CAS:528:DyaK1MXitFChs7k%3D
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470
-
(1999)
Ann Intern Med
, vol.130
, pp. 461-470
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
23
-
-
84897849395
-
Bendamustine-Bortezomib-Dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
-
PID: 24227817, COI: 1:CAS:528:DC%2BC2cXjt1altL8%3D
-
Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weissmann A, Adam Z (2014) Bendamustine-Bortezomib-Dexamethasone (BBD) is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 123:985–991
-
(2014)
Blood
, vol.123
, pp. 985-991
-
-
Ludwig, H.1
Kasparu, H.2
Leitgeb, C.3
Rauch, E.4
Linkesch, W.5
Zojer, N.6
Greil, R.7
Seebacher, A.8
Pour, L.9
Weissmann, A.10
Adam, Z.11
-
24
-
-
84973349244
-
-
Mateos M-V, Oriol A, Rosinol L, de Arriba F, Martin J, Martinez-Lopez J, Echeveste MA, Sarra J, Ramirez G, Ocio EM, Martinez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea A, Blade J, Lahuerta JJ, San Miguel JF (2013) Phase 2 study of bendamustine, bortezomib (Velcade) and prednisone (BVP) for newly diagnosed multiple myeloma blood (ASH Annual Meeting Abstracts) 122: 2155
-
(2013)
Phase 2 study of bendamustine, bortezomib (Velcade) and prednisone (BVP) for newly diagnosed multiple myeloma blood (ASH Annual Meeting Abstracts)
, vol.122
, pp. 2155
-
-
Mateos, M.-V.1
Oriol, A.2
Rosinol, L.3
de Arriba, F.4
Martin, J.5
Martinez-Lopez, J.6
Echeveste, M.A.7
Sarra, J.8
Ramirez, G.9
Ocio, E.M.10
Martinez, R.11
Palomera, L.12
Payer, A.13
Iglesias, R.14
de la Rubia, J.15
Alegre, A.16
Chinea, A.17
Blade, J.18
Lahuerta, J.J.19
San Miguel, J.F.20
more..
-
25
-
-
84897388164
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
-
Morabito F, Bringhen S, Larocca A, Wijermans P, Mateos VM, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Turel IA, Liberati MA, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M (2013) Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol. 2013. doi: 10.1002/ajh.23641
-
(2013)
Am J Hematol
, pp. 2013
-
-
Morabito, F.1
Bringhen, S.2
Larocca, A.3
Wijermans, P.4
Mateos, V.M.5
Gimsing, P.6
Mazzone, C.7
Gottardi, D.8
Omedè, P.9
Zweegman, S.10
Lahuerta, J.11
Zambello, R.12
Musto, P.13
Magarotto, V.14
Schaafsma, M.15
Oriol, A.16
Juliusson, G.17
Cerrato, C.18
Catalano, L.19
Gentile, M.20
Turel, I.A.21
Liberati, M.A.22
Cavalli, M.23
Rossi, D.24
Passera, R.25
Rosso, S.26
Beksac, M.27
Cavo, M.28
Waage, A.29
San Miguel, J.30
Boccadoro, M.31
Sonneveld, P.32
Palumbo, A.33
Offidani, M.34
more..
-
26
-
-
84888411774
-
Efficacy and tolerability of bendamustine bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase II study
-
Offidani M, Corvatta L, Maracci L, Liberati A.M, Ballanti S, Attolico I, Caraffa P, Alesiani F, Caravita di Toritto T, Gentili S, Tosi P, Brunori M, Derudas D, Ledda A, Gozzetti A, Cellini C, Malerba L, Mele A, Andriani A, Galimberti S, Mondello P, Pulini S, Coppetelli U, Fraticelli P Olivieri A, Leoni P (2013) Efficacy and tolerability of bendamustine bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase II study, Blood Cancer J Nov 22 (Epub ahead of print)
-
(2013)
Blood Cancer J Nov
, vol.22
, Issue.Epub ahead of print
-
-
Offidani, M.1
Corvatta, L.2
Maracci, L.3
Liberati, A.M.4
Ballanti, S.5
Attolico, I.6
Caraffa, P.7
Alesiani, F.8
Caravita di Toritto, T.9
Gentili, S.10
Tosi, P.11
Brunori, M.12
Derudas, D.13
Ledda, A.14
Gozzetti, A.15
Cellini, C.16
Malerba, L.17
Mele, A.18
Andriani, A.19
Galimberti, S.20
Mondello, P.21
Pulini, S.22
Coppetelli, U.23
Fraticelli P Olivieri, A.24
Leoni, P.25
more..
-
27
-
-
31344443373
-
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German study group of haematology and oncology (OSHO)
-
PID: 16402269
-
Pönisch W, Mitrou PS, Merkle K-H, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D (2006) Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone: a randomized phase III study of the East German study group of haematology and oncology (OSHO). J Cancer Res Clin Oncol 132:205–212
-
(2006)
J Cancer Res Clin Oncol
, vol.132
, pp. 205-212
-
-
Pönisch, W.1
Mitrou, P.S.2
Merkle, K.-H.3
Herold, M.4
Assmann, M.5
Wilhelm, G.6
Dachselt, K.7
Richter, P.8
Schirmer, V.9
Schulze, A.10
Subert, R.11
Harksel, B.12
Grobe, N.13
Stelzer, E.14
Schulze, M.15
Bittrich, A.16
Freund, M.17
Pasold, R.18
Friedrich, T.19
Helbig, W.20
Niederwieser, D.21
more..
-
28
-
-
84864375343
-
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
-
PID: 22526157
-
Pönisch W, Andrea M, Wagner I, Hammerschmidt D, Kreibich U, Schwarzer A, Zehrfeld T, Schwarz M, Winkelmann C, Petros S, Bachmann A, Lindner T, Niederwieser D (2012) Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 138:1405–1412
-
(2012)
J Cancer Res Clin Oncol
, vol.138
, pp. 1405-1412
-
-
Pönisch, W.1
Andrea, M.2
Wagner, I.3
Hammerschmidt, D.4
Kreibich, U.5
Schwarzer, A.6
Zehrfeld, T.7
Schwarz, M.8
Winkelmann, C.9
Petros, S.10
Bachmann, A.11
Lindner, T.12
Niederwieser, D.13
-
29
-
-
84876228632
-
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
-
PID: 23184429
-
Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Löschcke K, Krahl R, AL-Ali H, Niederwieser D (2013a) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol 139:499–508
-
(2013)
J Cancer Res Clin Oncol
, vol.139
, pp. 499-508
-
-
Pönisch, W.1
Bourgeois, M.2
Moll, B.3
Heyn, S.4
Jäkel, N.5
Wagner, I.6
Rohrberg, R.7
Hurtz, H.J.8
Schmalfeld, M.9
Aßmann, M.10
Edelmann, T.11
Mohren, M.12
Hoffmann, F.A.13
Becker, C.14
Schwarzer, A.15
Schönfelder, U.16
Zehrfeld, T.17
Hensel, G.18
Löschcke, K.19
Krahl, R.20
AL-Ali, H.21
Niederwieser, D.22
more..
-
30
-
-
84892674918
-
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure
-
PID: 24046251
-
Pönisch W, Moll B, Bourgeois M, Andrea M, Schliwa T, Heyn S, Schmalfeld M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Egert M, Stiegler R, Krahl R, Remane Y, Bachmann A, Lindner T, Weidhase L, Petros S, Fricke S, Vucinic V, Al Ali H, Niederwieser D (2013b) Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. J Cancer Res Clin Oncol 139:1937–1946
-
(2013)
J Cancer Res Clin Oncol
, vol.139
, pp. 1937-1946
-
-
Pönisch, W.1
Moll, B.2
Bourgeois, M.3
Andrea, M.4
Schliwa, T.5
Heyn, S.6
Schmalfeld, M.7
Edelmann, T.8
Becker, C.9
Hoffmann, F.A.10
Schwarzer, A.11
Kreibich, U.12
Egert, M.13
Stiegler, R.14
Krahl, R.15
Remane, Y.16
Bachmann, A.17
Lindner, T.18
Weidhase, L.19
Petros, S.20
Fricke, S.21
Vucinic, V.22
Al Ali, H.23
Niederwieser, D.24
more..
-
31
-
-
34347363426
-
Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease
-
Preiss R, Teichert J, Pönisch W, Niederwieser D, Matthias M, Merkle KH (2003) Pharmacokinetics and toxicity profile of bendamustine in multiple myeloma patients with end-stage renal disease. Hematolog J 4(Suppl. 1):263
-
(2003)
Hematolog J
, vol.4
, pp. 263
-
-
Preiss, R.1
Teichert, J.2
Pönisch, W.3
Niederwieser, D.4
Matthias, M.5
Merkle, K.H.6
-
32
-
-
84919474662
-
Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with relapsed/refractory Multiple myeloma: The Intergroupe Francophone du Myelome (IFM) 2009-01 protocol. Haematologica 97: e-Supplement 1
-
Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa A, Traullé C, Vilque J, Moreau P, Mathiot C, Avet-Loiseau H (2012) Bendamustine, bortezomib and dexamethasone (BVD) in elderly patients with relapsed/refractory Multiple myeloma: The Intergroupe Francophone du Myelome (IFM) 2009-01 protocol. Haematologica 97: e-Supplement 1, June 14-17, 2012, 400–401
-
(2012)
June
, vol.14-17
, Issue.2012
, pp. 400-401
-
-
Rodon, P.1
Hulin, C.2
Pegourie, B.3
Tiab, M.4
Anglaret, B.5
Benboubker, L.6
Jardel, H.7
Decaux, O.8
Kolb, B.9
Roussel, M.10
Garderet, L.11
Leleu, X.12
Royer, B.13
Banos, A.14
Benramdane, R.15
Cony-Makhoul, P.16
Dib, M.17
Fontan, J.18
Stoppa, A.19
Traullé, C.20
Vilque, J.21
Moreau, P.22
Mathiot, C.23
Avet-Loiseau, H.24
more..
-
33
-
-
77955985354
-
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
-
PID: 20510452, COI: 1:CAS:528:DC%2BC3cXhtV2itLfF
-
Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, Dimopoulos MA (2010) Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 34:1395–1397
-
(2010)
Leuk Res
, vol.34
, pp. 1395-1397
-
-
Roussou, M.1
Kastritis, E.2
Christoulas, D.3
Migkou, M.4
Gavriatopoulou, M.5
Grapsa, I.6
Psimenou, E.7
Gika, D.8
Terpos, E.9
Dimopoulos, M.A.10
-
34
-
-
84875840492
-
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
-
Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Dürk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W.; Study group indolent Lymphomas (StiL)
-
Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Dürk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W.; Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210
-
(2013)
Lancet
, vol.381
, Issue.9873
, pp. 1203-1210
-
-
-
35
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
PID: 18753647, COI: 1:CAS:528:DC%2BD1cXhtVGms77K
-
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
Dimopoulos, M.A.4
Shpilberg, O.5
Kropff, M.6
Spicka, I.7
Petrucci, M.T.8
Palumbo, A.9
Samoilova, O.S.10
Dmoszynska, A.11
Abdulkadyrov, K.M.12
Schots, R.13
Jiang, B.14
Mateos, M.V.15
Anderson, K.C.16
Esseltine, D.L.17
Liu, K.18
Cakana, A.19
van de Velde, H.20
Richardson, P.G.21
more..
-
36
-
-
84865171981
-
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
-
PID: 22802322, COI: 1:CAS:528:DC%2BC38XhsFertrfF
-
Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 30(24):2946–2955
-
(2012)
J Clin Oncol
, vol.30
, Issue.24
, pp. 2946-2955
-
-
Sonneveld, P.1
Schmidt-Wolf, I.G.2
van der Holt, B.3
El Jarari, L.4
Bertsch, U.5
Salwender, H.6
Zweegman, S.7
Vellenga, E.8
Broyl, A.9
Blau, I.W.10
Weisel, K.C.11
Wittebol, S.12
Bos, G.M.13
Stevens-Kroef, M.14
Scheid, C.15
Pfreundschuh, M.16
Hose, D.17
Jauch, A.18
van der Velde, H.19
Raymakers, R.20
Schaafsma, M.R.21
Kersten, M.J.22
van Marwijk-Kooy, M.23
Duehrsen, U.24
Lindemann, W.25
Wijermans, P.W.26
Lokhorst, H.M.27
Goldschmidt, H.M.28
more..
|